Intuitive Surgical announced a voluntary recall of a range of reusable da Vinci surgical instruments after a wave of safety complaints about frayed or broken grip cables. The recall covers forceps, scissors, drivers, and graspers that are used in robotic‑assisted procedures worldwide.
The recall includes specific models such as the da Vinci S and Si Double Fenestrated Grasper Instrument and the da Vinci S and Si Monopolar Curved Scissors Instrument. FDA enforcement reports indicate 2,370 units of the Double Fenestrated Grasper and 86,904 units of the Monopolar Curved Scissors are affected. The devices were distributed to hospitals and surgical centers in the United States and internationally, with confirmed sales in Argentina, Brazil, Canada, Chile, China, and Cyprus.
The recall follows an FDA enforcement report that identified the safety issue. Intuitive Surgical’s voluntary action is intended to address the cable failures and prevent potential harm to patients and surgeons. The company is working with distributors to replace or repair the affected instruments and to provide customer support for affected facilities.
Intuitive’s Q1 2026 financial results, released around the same time, show revenue of $2.77 billion, up 23% year‑over‑year, and non‑GAAP earnings per share of $2.50, up 38% year‑over‑year. Instruments and accessories revenue reached $1.69 billion, a 23% increase from $1.37 billion in Q1 2025. The recall could impact recurring revenue from instrument sales, but the current performance remains robust and the company’s margin expansion signals strong cost control.
Following the earnings release, analysts reacted positively to the strong financial performance, with a 7.16% rise in the company’s market value on April 22. The recall is viewed as a headwind, but it is outweighed by the earnings beat and the company’s continued growth in system and procedure volumes.
CEO Dave Rosa expressed satisfaction with the company’s performance, noting the continued adoption of the da Vinci 5 system and the expansion of the Ion platform. CFO Jamie Samath highlighted the strong revenue growth and margin expansion, underscoring the company’s operational efficiency.
The recall may lead to replacement costs, increased customer support, and potential reputational impact. However, Intuitive remains the dominant player in robotic surgery, and the recall is part of ongoing regulatory scrutiny that the company is addressing proactively.
The recall is ongoing; Intuitive is coordinating with distributors and customers to resolve the issue and to ensure compliance with FDA requirements.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.